AzTrials
AzTrials

Parkinson DiseaseNCT07599696

Speech Amplification Devices for Parkinson Disease: Talker- and Technology-Driven Enhancements

A study testing Behavioral speech strategies + speech amplification in people with Parkinson Disease and Atypical Parkinsonism, run by Michigan State University at 1 site in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The proposed research aims to investigate the use of speech amplification devices as a potential treatment option for people with Parkinson's disease and related disorders who exhibit hypophonia, a voice disorder that affects over half of those with Parkinson's disease. Read more about this study

Who is it for?
Ages 50 years and older
Conditions the study is for
Parkinson Disease, Atypical Parkinsonism
What is being tested?
Behavioral speech strategies + speech amplification
Could I receive a placebo?
No, everyone receives an active treatment
How many people
100 participants
Where
1 siteUnited States
Study dates
1 Mar 2024to 31 May 2028
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 50 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Dominant speakers of North American English
  • Have received a neurologist's diagnosis of Parkinson disease or parkinsonism (e.g., PSP/MSA/PSP)
  • Present with changes in their speech/voice

Who cannot join

  • History of any other speech, language, or neurological concern other than Parkinson/parkinsonism.
  • Uncorrected hearing loss that exceeds a threshold of 40 dB HL in more than one ear (as per baseline screening audiometry) and/or use of a cochlear implant.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Thea Knowles, PhD contact

517-353-6401

thea@msu.edu

United States1 site, 1 recruiting
  • Michigan State University

    East Lansing, Michigan, 48823

    Thea Knowles, PhD, 517-353-6401, thea@msu.edu

    Thea Knowles, PhD

    Recruiting

Other trials in United States

About this study

Official title: Speech Amplification Devices for Parkinson and Related Diseases: Talker- and Technology-Driven Enhancements

The proposed research aims to investigate the use of speech amplification devices as a potential treatment option for people with Parkinson's disease and related disorders who exhibit hypophonia, a voice disorder that affects over half of those with Parkinson's disease. By characterizing the acoustic and perceptual effects of speech amplification and identifying ways to optimize outcomes through talker- and device-specific enhancements, this project seeks to develop personalized, evidence-based treatment options for hypophonia. The current proposal will move this effort forward by systematically eliciting and modifying speech amplification device output that leverage both behavioral and technological approaches.

Read the detailed description

Though intensive behavioral speech intervention is considered the "gold standard" for treating hypophonia in Parkinson's disease (PD), many individuals struggle to transfer or maintain these behavioral strategies into their daily communication. This is because PD, affecting over six million people worldwide, is a progressive, neurodegenerative disorder that also impairs cognition, sensorimotor integration, and fatigue. Speech amplification devices are a type of augmentative technology that have been shown to improve communication related outcomes in PD. Amplification devices increase the volume of a person's natural speech and can be used on their own or to augment behavioral speech outcomes. The specific acoustic mechanisms underlying these benefits are unknown, though previous evidence suggests that increased signal intensity alone is not responsible for improved auditory-perceptual outcomes. The overall goal of this proposal is to identify the relationship between acoustic and perceptual consequences of amplification devices with and without the use of behavioral speech strategies. Aim 1 of this proposal will quantify the acoustic and auditory-perceptual effects of speech amplification devices for talkers with PD. In addition to using an amplification device, participants will speak with both their habitual speech style and a hyperarticulated, clear speech style. Aim 2 will identify the contribution of resultant acoustic features as well as targeted acoustic enhancements that optimize intelligibility in amplified speech. Acoustic modifications that impact the relative contributions of low to high frequency spectral energy will be made to a subset of the speech recordings from Aim 1. These acoustic enhancements will serve to simulate potential technological improvements to amplification devices. Naïve listeners will hear the speech recordings made in Aims 1 and 2 and will provide measures of listener accuracy and effort. Improvements in speech intelligibility of amplified speech are hypothesized to be associated with acoustic measures that reflect relative greater high to low frequency components of the speech signal. The most positive change is hypothesized to occur when talkers combine behavioral speech strategies with amplification compared to behavioral changes or amplified speech alone. Furthermore, auditory-perceptual outcomes are hypothesized to improve following implementation signal enhancements that could be directly integrated into future amplification device development. Collectively, this study will identify ways to maximize speech treatment outcomes of speech amplification devices through behavioral changes made by the talker or acoustic enhancements to the device output itself. Results will guide behavioral treatment strategies and future device modifications that will improve the efficacy of speech amplifiers in this population. This work is innovative for establishing ways to leverage behavioral speech strategies with advances in augmentative technology for PD. It is theoretically significant for defining the role of spectral acoustics in auditory-perceptual outcomes in disordered speech. It is clinically significant for advancing patient-centered augmentative speech treatment technology for PD.

Being tested
Behavioral speech strategies + speech amplification
Keywords
speech, Parkinson's disease, atypical parkinsonism, speech acoustics, speech-language pathology, hypophonia, voice, voice disorders, speech disorders, dysarthria
Medical subject headings
Parkinson Disease, Speech, Voice Disorders, Speech Disorders, Dysarthria

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Behavioral speech strategies + speech amplificationBehavioural

    Behavioral speech strategies + speech amplification

Study groups in NCT07599696
Study groupRoleWhat they receive
Speech StudyExperimentalSingle arm study: All speech conditions are administered.
Receives: Behavioral: Behavioral speech strategies + speech amplification

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Speech intensity

    Decibel sound pressure level (dB SPL) measured from speech audio recordings

    Measured: Day 1

  2. Voice quality

    Cepstral peak prominence smoothed (CPPS), measured in decibels (dB) from speech audio recordings

    Measured: Day 1

  3. Articulation

    Quadrilateral vowel articulation index, measured as a composite of first and second formants in Herz (Hz) across four vowels in speech audio recordings.

    Measured: Day 1

Secondary outcomes (2)
  1. Speech intelligibility

    % words correctly understood by naive listeners (0% = no words correctly transcribed; 100% = all words correctly transcribed). Listener participants transcribe speech recorded by speaker participants.

    Measured: From end of speech study enrollment to within 1 year. Perceptual measures are elicited from naive listeners following the speech recording study.

  2. Perceived Listener Effort

    % along a visual analogue scale (0 = "no effort required to understand the speech"; 100 = "maximal effort required to understand the speech"). Listener participants will rate speech recorded by speaker participants.

    Measured: From end of speech study enrollment to within 1 year. Listener effort will be elicited from naive listeners following the speech recording study.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 May 2026
  2. Study start1 Mar 2024
  3. Primary completion31 Dec 2027 (estimated)
  4. Study completion31 May 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
100 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07599696
Sponsor's protocol ID
00008898
Other IDs
R21DC021798, CurePSP CARES Grant - Knowles
Status last verified
May 2026
First submitted
5 May 2026
Last updated
20 May 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A study testing Behavioral speech strategies + speech amplification in people with Parkinson Disease and Atypical Parkinsonism, run by Michigan State University at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 20 May 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Thea Knowles, PhD (517-353-6401, thea@msu.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Speech intensity (time frame: Day 1). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 May 2026; AzTrials last refreshed its copy on 26 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in